What's Happening?
NEXTBIOMEDICAL CO., LTD., a South Korean medical device company, has announced an exclusive distribution agreement with Asahi Intecc Co., Ltd. for its product Nexsphere-F in Japan. Nexsphere-F is a fast-resorbable microsphere used for embolization, a medical procedure
to block blood flow to certain areas. This agreement marks a significant step in NEXTBIOMEDICAL's global expansion strategy, leveraging Asahi Intecc's established sales network in Japan. Asahi Intecc, known for its medical microcatheters and guidewires, will facilitate the entry of Nexsphere-F into the Japanese market. The product has already received regulatory approvals in Korea, Europe, and Canada, and is undergoing clinical trials for U.S. FDA approval.
Why It's Important?
This agreement is crucial for NEXTBIOMEDICAL as it aims to expand its market presence in Japan, a key region for medical device innovation and sales. By partnering with Asahi Intecc, NEXTBIOMEDICAL can tap into a well-established network of physicians and healthcare facilities, potentially accelerating the adoption of Nexsphere-F. The collaboration could enhance the availability of advanced embolization treatments in Japan, benefiting patients with musculoskeletal pain. Additionally, this move aligns with the growing demand for minimally invasive medical procedures, which are becoming increasingly popular due to their reduced recovery times and lower risk of complications.
What's Next?
NEXTBIOMEDICAL plans to pursue PMDA approval and reimbursement processes in Japan in collaboration with Asahi Intecc. The company aims to achieve significant market penetration by working closely with local physicians and partners. The ongoing clinical trials for U.S. FDA approval are expected to conclude between 2027 and 2028, potentially opening another major market for Nexsphere-F. As the product gains traction in Japan, NEXTBIOMEDICAL may explore further international expansion opportunities, leveraging the success of this partnership.
